HomeInsightsPE

Dr Reddys Laboratories Ltd PE Ratio

Dr Reddys Laboratories Ltd PE Ratio

stocks purchased

₹ 7.2 Cr

Volume transacted

stocks purchased

10.9 K

stocks traded

Last Updated time: 13 Oct 9.00 AM

Image

Dr Reddys Laboratories Ltd

NSE: DRREDDY

PE

19.8

Last updated: 13 Oct 9.00 AM

Key Highlights

  • The P/E Ratio of Dr Reddys Laboratories Ltd is 19.8 as of 13 Oct 9.00 AM.
  • The P/E Ratio of Dr Reddys Laboratories Ltd changed from 23.6 on March 2019 to 18.4 on March 2024 . This represents a CAGR of -4.06% over 6 years. .
  • The Latest Trading Price of Dr Reddys Laboratories Ltd is ₹ 6601 as of 11 Oct 15:30.
  • The PE Ratio of Pharmaceuticals Industry has changed from 28.2 to 27.1 in 5 years. This represents a CAGR of -0.79%.
  • The PE Ratio of Automobile industry is 20.2. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.3. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 158.1. The PE Ratio of Textiles industry is 37.6. In 2024.

Historical P/E Ratio of Dr Reddys Laboratories Ltd

No data available

Company Fundamentals for Dr Reddys Laboratories Ltd

No data available

Image

Dr Reddys Laboratories Ltd

NSE: DRREDDY

PRICE

6601.25

18.80 (0.29%)

stock direction

Last updated: 11 Oct 15:30

Market price Over Time

1M

1Y

3Y

5Y

Monitoring Dr Reddys Laboratories Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPriceleft
11 Oct 20246601.25
10 Oct 20246582.45
09 Oct 20246668.95
08 Oct 20246659.65
07 Oct 20246605.7
04 Oct 20246635.5
03 Oct 20246734.7
01 Oct 20246746.95
30 Sep 20246757.9
27 Sep 20246754.8

SWOT Analysis Of Dr Reddys Laboratories Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Dr Reddys Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value of Dr Reddys Laboratories Ltd

Market Value

0

Asset Value

0

* All values are in Rupees

Competitive Comparison of P/E Ratio

Company NamePEMarket Cap (INR Cr.)
Dr Reddys Laboratories Ltd191,10,159
Sun Pharmaceuticals Industries Ltd434,56,342
Divis Laboratories Ltd971,63,028
Cipla Ltd291,28,827
Torrent Pharmaceuticals Ltd701,18,373
Mankind Pharma Ltd571,11,956

Key Valuation Metric of Dr Reddys Laboratories Ltd

No data available

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Historical Market Cap of Dr Reddys Laboratories Ltd

No data available

* All values are in crore

Historical Revenue of Dr Reddys Laboratories Ltd

No data available

* All values are in crore

Historical EBITDA of Dr Reddys Laboratories Ltd

No data available

* All values are in crore

Historical Net Profit of Dr Reddys Laboratories Ltd

No data available

* All values are in crore

Historical Dividend Payout of Dr Reddys Laboratories Ltd

No data available

* All values are in %

About Dr Reddys Laboratories Ltd

  • Dr Reddy's Laboratories Ltd (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
  • Through its three businesses - Pharmaceutical Services &Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations.
  • The company's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
  • Dr. Reddy's operates in markets across the globe.
  • Its major markets include - USA, India, Russia & CIS countries, and Europe. Dr Reddy's Laboratories was incorporated in the year 1984 in Hyderabad.

Dr Reddys Laboratories Ltd News Hub

News

Aurigene Oncology receives nod for Phase 2 clinical trial for Ribrecabtagene autoleucel

Aurigene Oncology, a wholly-owned subsidiary of Dr. Reddy's Laboratories has announced the...

Read more

08 Oct 202418:16

News

Dr Reddys announces incorporation of new step-down subsidiary in Denmark

Dr. Reddy's Laboratories SA, Switzerland, (DRSA) a wholly owned subsidiary of  Dr Reddys ...

Read more

05 Oct 202411:37

News

Dr Reddys acquires Haleon plc brands in NRT category

Dr Reddys Laboratories announced that its wholly owned subsidiary, Dr. Reddy's Laboratorie...

Read more

30 Sep 202417:31

News

Dr Reddys Laboratories schedules board meeting

Dr Reddys Laboratories will hold a meeting of the Board of Directors of the Company on 5 N...

Read more

23 Sep 202410:11

News

Dr Reddys Laboratories Ltd down for fifth straight session

Dr Reddys Laboratories Ltd is down for a fifth straight session today. The stock is quotin...

Read more

19 Sep 202413:35

News

Dr. Reddy's API manufacturing unit (CTO-6) completes USFDA inspection

Dr. Reddy's Laboratories has received the Establishment Inspection Report (EIR) for its AP...

Read more

06 Sep 202409:14

Product Composition

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

FAQs for PE of Dr Reddys Laboratories Ltd

What is the current PE Ratio of Dr Reddys Laboratories Ltd?

The Current PE Ratio of Dr Reddys Laboratories Ltd is 19.79 as on 13 Oct 2024.

What is the average PE Ratio of the Pharmaceuticals industry?

The average industry PE Ratio of Pharmaceuticals is 40.0 as on 13 Oct 2024.

What was the PE Ratio of Dr Reddys Laboratories Ltd last year?

The PE Ratio of Dr Reddys Laboratories Ltd was 17.08 last year, now the PE ratio is 19.79, showing a year-on-year growth of 15.9%.

What does the PE Ratio of Dr Reddys Laboratories Ltd indicate about its stock?

The PE Ratio of Dr Reddys Laboratories Ltd is 19.79. This ratio indicates that investors are willing to pay 19.79 times the earnings per share for each share of Dr Reddys Laboratories Ltd.

What is the PE Ratio Growth of Dr Reddys Laboratories Ltd in comparison to its Earnings per Share (EPS) growth rate?

The PE Ratio of Dr Reddys Laboratories Ltd grew by 15.9% whereas, the EPS ratio grew by 6.3.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199*